Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC Taskforce Recommendations

Author:

Lippi Giuseppe12,Adeli Khosrow13,Ferrari Maurizio14,Horvath Andrea R.15,Koch David16,Sethi Sunil17,Wang Cheng-Bin18

Affiliation:

1. IFCC Taskforce on COVID-19, International Federation of Clinical Chemistry and Laboratory Medicine , Milan , Italy

2. Section of Clinical Biochemistry, Department of Neuroscience, Biomedicine and Movement , University Hospital of Verona, University of Verona , Piazzale L.A. Scuro, 10 , 37134 Verona , Italy

3. Clinical Biochemistry, The Hospital for Sick Children, University of Toronto , Toronto, ON , Canada

4. Vita-Salute San Raffaele University , Milan , Italy

5. Department of Clinical Chemistry and Endocrinology , New South Wales Health Pathology, Prince of Wales Hospital , Sydney , Australia

6. Department of Pathology and Laboratory Medicine , Emory University, and Director of Clinical Chemistry, Grady Memorial Hospital , Atlanta, GA , USA

7. Department of Laboratory Medicine , National University Hospital , Singapore , Singapore

8. Department of Laboratory Medicine , Chinese PLA General Hospital , Beijing , P.R. China

Abstract

Abstract Coronavirus disease 2019 (COVID-19) is the third coronavirus outbreak that has emerged in the past 20 years, after severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). One important aspect, highlighted by many global health organizations, is that this novel coronavirus outbreak may be especially hazardous to healthcare personnel, including laboratory professionals. Therefore, the aim of this document, prepared by the COVID-19 taskforce of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), is to provide a set of recommendations, adapted from official documents of international and national health agencies, on biosafety measures for routine clinical chemistry laboratories that operate at biosafety levels 1 (BSL-1; work with agents posing minimal threat to laboratory workers) and 2 (BSL-2; work with agents associated with human disease which pose moderate hazard). We believe that the interim measures proposed in this document for best practice will help minimazing the risk of developing COVID-19 while working in clinical laboratories.

Publisher

Walter de Gruyter GmbH

Subject

Biochemistry (medical),Clinical Biochemistry,General Medicine

Cited by 40 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3